Prevention of disease Archives - Page 2 of 8

Home
/
Projects
/

Prevention of disease

Prevention of disease refers to the ability of the vaccine to protect individuals from becoming sick from the tuberculosis (TB) bacteria after exposure to it. It does not necessarily prevent a person from getting infected with the TB bacteria.

How to introduce new TB vaccine in adolescents and adults: Insights from Key Stakeholders in Mozambique, Southern Africa

2024-2026

Hypothetical vaccines

Assesses stakeholder perspectives on introducing a new TB vaccine in Mozambique, including with high-risk groups should be prioritised, challenges in reaching different populations, expected vaccine uptake and coverage, and appropriate delivery stategies.

Target Tuberculosis vaccination strategies in the United States

2026

Hypothetical vaccines

Uses a mathematical model to evaluate targeted TB vaccination strategies in the United States. The study examines which high-risk groups should be prioritised for a future adult TB vaccine, including people living with HIV, people with medical comorbidities, and people born outside the United States

Attitudes towards new tuberculosis vaccines among adults, adolescents and their caregivers in southern Mozambique

2024

Hypothetical vaccines

We investigated willingness to be vaccinated with a new TB vaccine in a high HIV and TB burden setting in southern Mozambique in 2024 using a mixed methods approach involving a cross-sectional survey and concurrent in-depth interviews.

Advancing national preparedness for the introduction of novel tuberculosis vaccines in South Africa

2025-2026

M72/AS01e, MTBVAC

The workshop aimed to align stakeholders on priority populations and delivery strategies for future TB vaccines, identify evidence needs to inform national policy decision-making, and outline actions required to ensure timely and equitable introduction.

A model for the epidemiological impact of tuberculosis policy options

2026

Hypothetical vaccines

Develops a new TB transmission model to help decision-makers comapre the epidemiological impact of different TB interventions and allocate resources. The model incorporates diagnosis, treatment, drug resistance, HIV status, age, and vaccination status, and was calibrated using data from 29 high burden countries. It demonstrates the potential impact of comprehensive TB interventions in Indonesia and Nigeria, including the possible use of a post-exposure TB vaccine

Community willingness towards a hypothetical new TB vaccine

2026

Hypothetical vaccines

Qualitative study exploring community willingness to accept a future TB vaccine in Nepal. It examines how knowledge, previous vaccination experiences, trust in health services, misinformation, perceived safety and effectiveness, costs, transportation, service delivery barriers and gender rleated actor influence willingness to receive a new TB vaccine

Global impact and cost-effectiveness of tuberculosis interventions

2026

Hypothetical vaccines

The modelling study compares the population-level impact and cost-effectiveness of TB vaccination with other TB interventions. It models vaccination scale-up in Brazil, India, and South Africa and estimates that vaccination could prevent 15-28% of symptomatic TB episodes by 2050. It provides evidence to inform investment, policy, and planning for future TB vaccine introduction and scale-up.

The potential health and economic impact of introducing the vaccine candidate VPM1002 to prevent tuberculosis disease in low- and middle-income countries

2026

VPM1002

This study estimates the potential health and economic impact of introducing the TB vaccine candidate VPM1002 in 79 low- and middle- income countries. It models routine vaccination and vaccination campaigns, estimating TB cases and deaths averted and the cost-effectiveness of different introduction scenarios. It provides evidence for decisions about the potential future introduction and scale-up of VPM1002

Facing up to reality? What to do if M72/AS01E doses are limited

M72/AS01e

The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a positive result, could be licensed by 2030. Modelling suggested a large potential impact from introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding the allocation of constrained doses on the potential global impact of M72/AS01E

The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries

2023

Hypothetical vaccines

Estimates the potential economic impact of introducing novel TB vaccines in 105 low- and middle- income countries. It compares ifnant and adolescents/ adult vaccination scenarios and models their effects on TB- related mortality, morbidity, healthcare costs and GDP. Finding support decision making on the future development and introduciton of novel TB vaccines